{"nctId":"NCT01494467","briefTitle":"Phase 3 Papulopustular Rosacea Study","startDateStruct":{"date":"2011-12"},"conditions":["Papulopustular Rosacea"],"count":688,"armGroups":[{"label":"CD5024","type":"EXPERIMENTAL","interventionNames":["Drug: CD5024"]},{"label":"CD5024 Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Azelaic acid 15% Gel"]}],"interventions":[{"name":"CD5024","otherNames":[]},{"name":"Azelaic acid 15% Gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),\n2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.\n\nExclusion Criteria:\n\n1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,\n2. The subject has rosacea with more than two nodules on the face.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Success Rate","description":"Percentage of subjects who achieve \"Clear\" (Score 0) or \"Almost Clear\" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.\n\nEvaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:\n\nClear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Absolute Change in Inflammatory Lesion Count","description":"Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":"14.87"},{"groupId":"OG001","value":"-13.4","spread":"14.48"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)","description":"Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.7","spread":"33.18"},{"groupId":"OG001","value":"-43.4","spread":"38.42"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":458},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Skin irritation"]}}}